STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Drug Design & Discovery Review Article

Review of Atorvastatin As A Potent Drug For Cardio-Vascular Disease(CVD)

  1. Usama Kasam Rinde Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi
  2. Sonali Dheeraj Parab Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi
  3. Aarya Abhijit Tanawade Department of Pharmacy, SSPM’S V P College of Pharmacy Madkhol-Sawantwadi
  4. Nikhil Mangesh Patil Department of Pharmacy, SVS's Dadasaheb Rawal Pharmacy College, Mandal- Dondaicha

Abstract

Cardiovascular disease (CVD), particularly atherosclerosis, remains the leading cause of death worldwide, significantly burdening public health, especially in Western societies. Metabolic syndrome and arrhythmic complications further exacerbate cardiovascular morbidity and mortality. Among restorative specialists, statins particularly atorvastatin have gotten to central in both the essential and auxiliary anticipation of coronary heart infection (CHD) due to their strong lipid-lowering properties and additional pleiotropic impacts. Atorvastatin, a selective HMG-CoA reductase inhibitor, not only reduces low-density lipoprotein cholesterol (LDL-C) by up to 60% but also improves endothelial function, decreases oxidative stress, and stabilizes atherosclerotic plaques. Long half-life and liver selectivity, advantageous pharmacokinetic profiles promote its effectiveness. Clinical studies such as Ascot-LLa, TNT, and CARDs have reduced the benefits of reducing important unwanted cardiovascular events, particularly in high-risk patients, including older adults. Despite some instances of statin intolerance, atorvastatin maintains a strong safety and efficacy record. With its broad cardiovascular benefits, cost-effectiveness, and growing role in personalized medicine, atorvastatin remains a cornerstone of modern cardiovascular risk management.

Keywords

References (33)

  1. Kjekshus J. Arrhythmias and mortality in congestive heart failure. The American journal of cardiology. 1990 May 22;65(19):42-8.
  2. Liptak B, Knezl V, Gasparova Z. Anti-arrhythmic and cardio-protective effects of atorvastatin and a potent pyridoindole derivative on isolated hearts from rats with metabolic syndrome. Bratislava Medical Journal. 2019;120(03):200-206. doi:10.4149/bll_2019_034
  3. Roy D, Mahapatra T, Manna K, Kar A, Rana MS, Roy A, et al. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. PLOS ONE. 2020;15(5):e0233230. doi:10.1371/journal.pone.0233230
  4. Elmadbouh I, Mansour M, Nabeh M, Faried W, Abdelsabour A, Omar A. Atorvastatin improves cardiac function and remodeling in chronic non-ischemic heart failure: A clinical and pre-clinical study. The Egyptian Heart Journal. 2015;67(4):289-298. doi:10.1016/j.ehj.2014.11.003
  5. Welty FK. Atorvastatin and cardiovascular risk in the elderly – patient considerations. Clinical Interventions in Aging. 2008;Volume3:299-314. doi:10.2147/cia.s2442
  6. Godoy JC, Niesman IR, Busija AR, Kassan A, Schilling JM, Schwarz A, et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. The FASEB Journal. 2018;33(1):1209-1225. doi:10.1096/fj.201800876r
  7. Liao JK. Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 2005;96(5):24-33. doi:10.1016/j.amjcard.2005.06.009
  8. Sai C, Li J, Ruiyan M, Yingbin X. Atorvastatin prevents postoperative atrial fibrillation in patients undergoing cardiac surgery. Hellenic Journal of Cardiology. 2019;60(1):40-47. doi:10.1016/j.hjc.2017.12.012
  9. Virani PA, Sojitra RA, Raj HA, Jain VI. A review on Irbesartan co administered with Atorvastatin for the treatment of cardiac risk. J Crit Rev. 2014;1(1):25-8.
  10. Raschi E, Casula M, Cicero AFG, Corsini A, Borghi C, Catapano A. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacology & Therapeutics. 2023;250:108507. doi:10.1016/j.pharmthera.2023.108507
  11. Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events. Korean Circulation Journal. 2017;47(4):432. doi:10.4070/kcj.2016.0406
  12. Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clinical Research in Cardiology. 2016;105(9):783-790. doi:10.1007/s00392-016-0991-z
  13. Kapur N. Clinical efficacy and safety of statins in managing cardiovascular risk. Vascular Health and Risk Management. 2008;Volume4:341-353. doi:10.2147/vhrm.s1653
  14. Q. Zhou and J. K. Liao, “Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy.”
  15. Sawada N, Liao JK. Rho/Rho-Associated Coiled-Coil Forming Kinase Pathway as Therapeutic Targets for Statins in Atherosclerosis. Antioxidants & Redox Signaling. 2014;20(8):1251-1267. doi:10.1089/ars.2013.5524
  16. Banach M, Mikhailidis DP. Statin Intolerance. Cardiology Clinics. 2018;36(2):225-231. doi:10.1016/j.ccl.2017.12.004
  17. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of Statins on Skeletal Muscle Function. Circulation. 2013;127(1):96-103. doi:10.1161/circulationaha.112.136101
  18. Bouillon K, Baricault B, Semenzato L, Botton J, Bertrand M, Drouin J, et al. Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study. Journal of the American Heart Association. 2022;11(12). doi:10.1161/jaha.121.023357
  19. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, et al. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery. JAMA. 2016;315(9):877. doi:10.1001/jama.2016.0548
  20. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion. 2008;24(4):1217-1229. doi:10.1185/030079908x292001
  21. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. International Journal of Cardiology. 2013;168(6):5126-5134. doi:10.1016/j.ijcard.2013.07.113
  22. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Canadian Medical Association Journal. 2011;183(16):E1189-E1202. doi:10.1503/cmaj.101280
  23. Murphy WA, Lin N, Damask A, Schwartz GG, Steg PG, Szarek M, et al. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation: Genomic and Precision Medicine. 2022;15(3). doi:10.1161/circgen.121.003503
  24. V. Singh and P. Deedwania, “Vascular Health and Risk Management Reducing morbidity and mortality in high risk patients with statins,” 2009. [Online]. Available: www.dovepress.com
  25. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends in Immunology. 2007;28(2):88-98. doi:10.1016/j.it.2006.12.003
  26. P. S. Sever et al., “Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA),” 2005. [Online]. Available: www.ascotstudy.
  27. Opie LH, Dalby AJ. Cardiovascular prevention: Lifestyle and statins – competitors or companions? South African Medical Journal. 2014;104(3):168. doi:10.7196/samj.7942
  28. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013;2021(9). doi:10.1002/14651858.cd004816.pub5
  29. Yamamuro S, Shinozaki T, Iimuro S, Matsuyama Y. Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin’s effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Statistical Methods in Medical Research. 2021;30(8):1782-1799. doi:10.1177/09622802211025988
  30. Davignon J. Beneficial Cardiovascular Pleiotropic Effects of Statins. Circulation. 2004;109(23_suppl_1). doi:10.1161/01.cir.0000131517.20177.5a
  31. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research. 2017;120(1):229-243. doi:10.1161/circresaha.116.308537
  32. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. New England Journal of Medicine. 2008;359(8):789-799. doi:10.1056/nejmoa0801936
  33. Loch A, Bewersdorf JP, Kofink D, Ismail D, Abidin IZ, Veriah RS. Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Research Notes. 2017;10(1). doi:10.1186/s13104-017-2617-6
Support